| Literature DB >> 28340877 |
Christopher Dittus1, J Mark Sloan2.
Abstract
Adult T-cell leukemia/lymphoma (ATLL) is a rare T-cell disorder that is etiologically linked to chronic infection with human T-cell lymphotropic virus type 1. ATLL is divided into four subtypes: acute, lymphomatous, chronic, and smoldering. The acute and lymphomatous variants are often described clinically as the aggressive types of ATLL. Treatment strategies traditionally have focused on antiviral therapy with zidovudine and interferon-alpha and combination chemotherapy. Novel therapeutic approaches include the use of monoclonal antibodies, anti-CCR4 therapy, immunomodulatory therapy, and anti-TAX vaccines. Future research must focus on multi-institutional clinical trial participation because of the rarity of this deadly hematologic malignancy.Entities:
Keywords: Aggressive lymphoma; HTLV-1; Hypercalcemia; Leukemia; Lymphoma; Rare cancer; T-cell lymphoma
Mesh:
Substances:
Year: 2017 PMID: 28340877 DOI: 10.1016/j.hoc.2016.11.005
Source DB: PubMed Journal: Hematol Oncol Clin North Am ISSN: 0889-8588 Impact factor: 3.722